BioNTech SE nelle notizie
Immunoterapie innovative contro le malattie
Tamtam ha trovato 20 articoli recenti su BioNTech SE.
- BioNTech SE : Gets a Buy rating from Berenberg
- Morgan Stanley sets a Buy rating for BioNTech stock
- BNTX Maintained by Morgan Stanley -- Price Target Lowered to $11
- Berenberg raises target for BioNTech stock from USD 132 to USD 140
- BioNTech (BNTX) CEO Ugur Sahin sells 72,000 and 21,000 shares under a June 3 trading plan.
- BioNTech stock fell 1.96 percent despite a Buy consensus
- BioNTech SE-Aktie nachbörslich bei 86,83 Euro: plus 0,85 Prozent
- BioNTech Aktie kaufen oder verkaufen: Analystenbewertungen im September `26
- BioNTech stock draws Moderate Buy consensus at USD 126 target
- BioNTech's Founders Map a Breakaway Venture as German Plants Face the Axe
- BioNTech SE: Moving Past Covid (NASDAQ:BNTX)
- BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading
- BioNTech stock faces a 59.5 percent Q2 revenue drop
- BioNTech meldet neue Gotistobart-Daten. BioNTech-Aktie kostet 86,10 Euro
- Biontech: 1800 Jobs weg, 3 Standorte dicht – jetzt eskaliert der Streit
- Die BioNTech-Aktie polarisiert: Das spricht jetzt für und gegen den nächsten Anstieg
- BOTSI®-Advisor Abstufung BioNTech von Rang 927 auf ... - boerse.de
- BioNTech (BNTX) CEO sells 17,000 shares twice under a preset trading plan
- Morgan Stanley sets USD 115 target for BioNTech stock
- BioNTech stock after-hours at EUR 86.05: minus 0.12 percent versus prior close
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come BioNTech SE?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili